Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NACL

Other

Phase 2/3 Most advanced trial (none active)
1 Registered trials

What is NACL?

NACL 0.9% is named as a saline dosing regimen in a trial of acetaminophen for closing the ductus arteriosus in extremely premature infants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Cardiovascular
In trials of
CNTB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04459117 Phase 2/3 Patency of the Ductus Arteriosus Completed CNTB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AcetaminophenExtreme PrematurityPatency of the Ductus Arteriosus

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.